Diabetes is a metabolic disorder that develops when the body is unable to produce or effectively use insulin the hormone ...
News Medical on MSN1h
Global gap in diabetes prevalence and treatment has widened since 1990Global diabetes rates have surged, particularly in low-resource areas, revealing critical gaps in treatment access and ...
Verywell Health on MSN16h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data ShowsEli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...
The long-term consequences of this metabolic dysfunction are extensive. (Image Credits: Pixabay) Diabetes risk and obesity: ...
For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase ...
A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback